The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | An update on the progress made in CAR T-cell therapy in India
Gaurav Narula, MD, Tata Memorial Center, Mumbai, India, provides an update on progress made in the CAR-T space in India. Dr Narula highlights the approval of actalycabtagene autoleucel (Actaly-cel™) for treating acute lymphoblastic leukemia (ALL) in patients over 15 years of age, with an ongoing pediatric investigation in a Phase Ib/II trial (CTRI/2023/03/050689). Additionally, a Phase II trial (CTRI/2022/03/041162) has been initiated to investigate varnimcabtagene autoleucel (var-cel) in relapsed/refractory (R/R) B-cell malignancies and a Phase I trial is being conducted to assess PRG1801 in multiple myeloma (MM). This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: ImmunoACT.
